BBT-401

BBT-401 is a first-in-class, orally administered, GI tract-restricted small molecule and synthetic lipidated tetrapeptide that acts as a selective inhibitor of Pellino E3 ubiquitin protein ligase 1 (Pellino-1). It disrupts Pellino-1 protein-protein interactions, thereby inhibiting the toll-like receptor (TLR)-mediated proinflammatory signaling pathway and reducing proinflammatory cytokine expression. The drug is being developed primarily for the treatment of ulcerative colitis and has shown efficacy in preclinical models by improving symptoms and histopathological parameters associated with colitis. It is not systemically absorbed after oral administration, which may contribute to its safety profile. The developer is Bridge Biotherapeutics[1][2][3][5][6][7].

Other names

Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate